Frederick Banting และ Charles Best ที่ University of Toronto
การรักษาครั้งแรกด้วยการฉีดอินซูลิน
ภาพก่อนและหลังของเด็กที่เป็นโรคเบาหวานชนิดที่ 1
Leonard Thompson เด็กชายอายุ 14 ปีที่มีนํ้าหนักมากกว่า 29 กิโลกรัม ได้กลายเป็นบุคคลแรกที่ได้รับการรักษาโรคเบาหวานด้วยอินซูลิน หลังจากได้รับการฉีด Banting และสารสกัด Best’s (เรียกว่า muck สีนํ้าตาลหนา) นํ้าตาลในเลือดของ Leonard
การรักษาครั้งแรกด้วยการฉีดอินซูลิน
Leonard Thompson เด็กชายอายุ 14 ปีที่มีนํ้าหนักมากกว่า 29 กิโลกรัม ได้กลายเป็นบุคคลแรกที่ได้รับการรักษาโรคเบาหวานด้วยอินซูลิน หลังจากได้รับการฉีด Banting และสารสกัด Best’s (เรียกว่า muck สีนํ้าตาลหนา) นํ้าตาลในเลือดของ Leonard
ภาพก่อนและหลังของเด็กที่เป็นโรคเบาหวานชนิดที่ 1
August and Marie Krogh
Insulin production begins in Scandinavia
1923
Nordisk Insulinlaboratorium commercialises the production of insulin after the extraction and purification technique is brought back to Denmark from Canada by August and Marie Krogh. With insulin, a person diagnosed with diabetes now has a dramatically improved life expectancy.
1923
Insulin production begins in Scandinavia
Nordisk Insulinlaboratorium commercialises the production of insulin after the extraction and purification technique is brought back to Denmark from Canada by August and Marie Krogh. With insulin, a person diagnosed with diabetes now has a dramatically improved life expectancy.
August and Marie Krogh
Novo Nordisk insulin production in the 1930s.
Hans Christian Hagedorn
NPH insulin decreases the burden of treatment
1946
Hans Christian Hagedorn discovers NPH (neutral protamine Hagedorn) insulin, which prolongs the effects of insulin and means that people with diabetes can have fewer injections.
1946
NPH insulin decreases the burden of treatment
Hans Christian Hagedorn discovers NPH (neutral protamine Hagedorn) insulin, which prolongs the effects of insulin and means that people with diabetes can have fewer injections.
Portable glucose meter simplifies diabetes monitoring
1970s
Practical self-monitoring of blood glucose (SMBG) is now possible with portable glucose meters, making it easier for people living with diabetes to manage their condition by using test strips at home.
1970s
Portable glucose meter simplifies diabetes monitoring
Practical self-monitoring of blood glucose (SMBG) is now possible with portable glucose meters, making it easier for people living with diabetes to manage their condition by using test strips at home.
Ames Reflectance Meter
Laboratory in Bagsværd, Denmark.
HbA1C in clinical practice
1970s
HbA1C – the average blood glucose level during the past 120 days – becomes the primary means of assessing blood glucose management and enables physicians to critically assess the impact of lifestyle changes and medication on long-term health outcomes.
1970s
HbA1C in clinical practice
HbA1C – the average blood glucose level during the past 120 days – becomes the primary means of assessing blood glucose management and enables physicians to critically assess the impact of lifestyle changes and medication on long-term health outcomes.
Laboratory in Bagsværd, Denmark.
First commercially available human insulin
1982
Insulin becomes the first therapeutic protein to be created using recombinant DNA technology. This ‘human insulin’ is identical to the insulin produced by our bodies, is highly purified and can be produced in unlimited quantities, greatly expanding access for people with diabetes.
1982
First commercially available human insulin
Insulin becomes the first therapeutic protein to be created using recombinant DNA technology. This ‘human insulin’ is identical to the insulin produced by our bodies, is highly purified and can be produced in unlimited quantities, greatly expanding access for people with diabetes.
Patient with an insulin pump.
The first “mini” insulin pump
1983
First developed in the 1960s, insulin pumps become widely available in the 1980s, ensuring people with diabetes can benefit from having their insulin released as and when required throughout the day. In the future, many will even work in concert with continuous glucose monitoring systems (CGM).
1983
The first “mini” insulin pump
First developed in the 1960s, insulin pumps become widely available in the 1980s, ensuring people with diabetes can benefit from having their insulin released as and when required throughout the day. In the future, many will even work in concert with continuous glucose monitoring systems (CGM).
Patient with an insulin pump.
การจัดการที่ง่ายและปลอดภัย – ปากกาอินซูลินด้ามแรก
กระบอกฉีดยา Novo ตั้งแต่ปี 1925 และอุปกรณ์ NovoPen® เครื่องแรกตั้งแต่ปี 1985
กระบอกฉีดยา Novo ตั้งแต่ปี 1925 และอุปกรณ์ NovoPen® เครื่องแรกตั้งแต่ปี 1985
Introduction of first generation insulin analogues
1996
Insulin analogues – a range of rapid-acting, long-acting and premixed formulations – are created to more closely mimic the body’s natural pattern of releasing insulin. Analogue insulins have modifications that ensure more predictable absorption, making it easier for people to plan around mealtimes, avoid low blood sugar levels and reduce the risk of weight gain.
1996
Introduction of first generation insulin analogues
Insulin analogues – a range of rapid-acting, long-acting and premixed formulations – are created to more closely mimic the body’s natural pattern of releasing insulin. Analogue insulins have modifications that ensure more predictable absorption, making it easier for people to plan around mealtimes, avoid low blood sugar levels and reduce the risk of weight gain.
InDuo combination insulin delivery device and blood sugar monitor from 2001.
First CGM system approved
1999
The first continuous glucose monitoring (CGM) device for reading blood glucose levels is approved by the FDA, bringing hope to people with diabetes who want to gain more control over their health.
1999
First CGM system approved
The first continuous glucose monitoring (CGM) device for reading blood glucose levels is approved by the FDA, bringing hope to people with diabetes who want to gain more control over their health.
InDuo combination insulin delivery device and blood sugar monitor from 2001.
Beyond insulin: new treatment options for type 2 diabetes
2005
Treatment options take type 2 diabetes care beyond blood sugar control with the introduction of GLP-1 agonists and, later, SGLT-2 inhibitors. The GLP-1 class of medicines reduce blood sugar levels by enhancing the natural secretion of insulin while also
reducing appetite and food intake.
2005
Beyond insulin: new treatment options for type 2 diabetes
Treatment options take type 2 diabetes care beyond blood sugar control with the introduction of GLP-1 agonists and, later, SGLT-2 inhibitors. The GLP-1 class of medicines reduce blood sugar levels by enhancing the natural secretion of insulin while also
reducing appetite and food intake.
Discovering and developing new protein and peptide-based therapies.
First oral GLP-1 treatment for type 2 diabetes
2019
A major breakthrough that further expands treatment options and reduces barriers, this innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many people living with type 2 diabetes.
2019
First oral GLP-1 treatment for type 2 diabetes
A major breakthrough that further expands treatment options and reduces barriers, this innovative tablet eliminates the need for injections with GLP-1 – a welcome relief for many people living with type 2 diabetes.
Discovering and developing new protein and peptide-based therapies.
Mandy Marquardt has type 1 diabetes, rides for Team Novo Nordisk and lives in USA.
